Healthcare / BiotechnologyTaipei Exchange
$69.20
+0.20 (+0.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-138.2M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$0
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4.5%
↓Gross Margin
71.6%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+217.1%
FCF CAGR
—
FCF margin
-379.2%
FCF / Net income
1.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $36.4M · net income $-114.1M · FCF $-138.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $36.4M | $36.4M | $32.0M | $18.9M | $1.1M |
| Net Income | $-114.1M | $-114.1M | $-82.5M | $-92.0M | $-254.2M |
| EBITDA | $-104.0M | $-104.0M | $-76.0M | $-80.7M | $-275.6M |
| EPS | — | — | -0.68 | -0.81 | -2.29 |
| Gross Margin | 71.6% | 71.6% | 27.1% | 59.2% | 93.3% |
| Operating Margin | -573.3% | -573.3% | -487.4% | -704.9% | -22806.7% |
| Net Margin | -313.1% | -313.1% | -257.6% | -486.6% | -22238.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.04 | 0.06 | 0.10 |
| Current Ratio | 9.19 | 9.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-138.2M | $-138.2M | $-293.5M | $-111.9M | $-238.4M |
| Returns | |||||
| ROE | -4.5% | -4.5% | -2.7% | -7.0% | -18.3% |
| Valuation | |||||
| P/B | 3.35 | 3.35 | 4.41 | 15.46 | 24.71 |
| Growth & Yield | |||||
| Revenue Growth | 13.8% | 13.8% | 69.4% | 1554.9% | — |
| EPS Growth | — | — | 16.0% | 64.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.68 → n/d
Residual
-38.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.